

Ref No : COL/RESULTS/Q4/2018-19

30/05/2019

To,
The Bombay Stock Exchange Limited
Phiroze Jeejeeboy Towers,
Dalal Street,
Mumbai - 400001

Dear Sir,

Sub: Outcome of Board Meeting held today i.e. 30th May, 2019 pursuant to Regulation 33 and Regulation 30 read with Part A of Schedule III of SEBI (LODR) Regulations, 2015.

The Meeting of Board of Directors was held on Thursday, 30th May, 2019 at 1.30 P.M at the registered office of the Company at A-101, Pratik Industrial Estate, Next to Fortis Hospital, Mulund Goregaon Link Road ,Mumbai -,400078 has, inter alia, approved the Audited Financial Results for the fourth quarter and financial year ended on 31st March, 2019.

Pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a copy of statement of Audited Financial Results and Auditor's Report on the Audited Financial Results for the fourth quarter and financial year ended 31st March, 2019 issued by Statutory Auditors, M/s. Vora & Associates, Chartered Accountants, enclosed herewith for your records and necessary dissemination.

The Meeting commenced at 1.30 P.M. and concluded at 3.00 P.M.

This is for your information and record.

Thanking you,

Yours faithfully,
FOR COLINZ LABORATORIES LTD

DR. MANI L. S.
(Director-Legal, Corporate Affairs & Company Secretary)

Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006

COLINZ LABORATORIES LIMITED.


(CIN NO : L24200MH1986PLC041128)

A-101, Pratik Industrial Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2019

"(Rs. In Lakhs)"

S. No.	Particulars	Audited	Un-audited	Audited	Audited	
		Quarter ended			YEAR ENDED	
		31-Mar-19	31-Dec-18	31-Mar-18	31-Mar-19	31-Mar-18
PART - I						
1	(a) Revenue from Operation	168.98	189.75	187.48	766.82	795.80
3	(b) Other Income	3.18	2.82	2.64	11.84	9.76
3	Total Income from Operation	172.16	192.57	190.12	778.66	805.56
4	Expenses					
	(a) Cost Of Material Consumed	15.94	19.74	6.45	93.34	145.37
	(b) Purchase of Stock in Trade	23.05	58.58	33.63	179.43	114.52
	(c) Change in Inventories Of Finished Goods and Work in Progress and Stock in Trade	36.35	(21.82)	(4.24)	7.69	10.39
	(d) Employee Benefit Expenses	61.08	96.97	88.82	336.66	339.27
	(e) Finance Cost	2.35	2.69	2.82	9.74	8.38
	(f) Depreciation & Amortisation Expenses	5.83	4.98	5.53	21.59	22.11
	(g) Other Expenses	24.99	28.95	53.69	114.64	150.39
	Total Expenses	169.59	190.09	186.70	763.09	790.43
5	Profit/(Loss) Before exceptional items and tax (3-4)	2.57	2.48	3.42	15.57	15.13
6	Exceptional items	-	-	-	-	-
7	Profit/(Loss) before tax (5-6)	2.57	2.48	3.42	15.57	15.13
8	Tax Expenses (Provision for Taxation) Current tax					
	i) Current Tax	4.99	0.50	5.58	6.99	7.68
	ii) Deffered Tax	(3.16)	-	(9.13)	(3.16)	(9.13)
	iii) Tax for earlier years	-	-	1.37	-	1.37
	iv) MAT Credit of Earlier years	(0.43)	-	(7.85)	(0.43)	(7.85)
9	Profit/(Loss) for the period from continuing operations(7-8)	1.17	1.98	13.45	12.17	23.06
10	Profit/(Loss) for the period	1.17	1.98	13.45	12.17	23.06
11	Other Comprehensive Income (Net of Tax)					
	A) Item that will not be reclassified to Profit or Loss Account					
	i) Change in fair value of investment in Equity Instruments	(0.20)	2.46	(8.15)	(3.01)	(0.20)
12	Total Comprehensive Income for the period (10+11) Comprising	0.97	4.44	5.30	9.16	22.86
13	Earning per equity share (for Continuing operation) (In Rs.)					
	i) Basic	0.02	0.10	0.12	0.20	0.50
	ii) Diluted	0.02	0.10	0.12	0.20	0.50



Colinz Laboratories Limited


CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006

STATEMENT OF ASSETS AND LIABILITIES			
Particulars		31-Mar-2019	31-Mar-2018
Non-Current Assets			
a) Property, Plants & Equipment		221.00	241.19
b) Capital Work-in progress		-	-
c) Intangible Assets		-	-
d) Financial Assets			
i) Investments		49.67	52.68
ii) Loans		-	-
iii) Other Financial Assets		-	-
e) Other Non Current Assets		82.75	110.46
Total Non-Current Assets		353.42	404.33
Current Assets			
a) Inventories		189.85	196.81
b) Financial Assets			
i) Trade Receivables		167.77	168.29
ii) Cash & Cash Equivalents		27.51	25.56
iii) Other Bank Balances		171.78	161.43
iv) Other Financial Assets		-	-
c) Other Current Assets		7.16	2.58
Total Current Assets		564.07	554.67
TOTAL ASSETS		917.49	959.00
EQUITY AND LIABILITIES			
Equity			
a) Equity Share Capital		354.41	354.41
b) Other Equity		329.84	320.68
Total Equity		684.25	675.09
Liabilities			
Non-Current Liabilities			
a) Deferred Tax Liabilities (Net)		28.93	32.09
b) Other Non Current Liabilities		25.69	40.24
Total Non-Current Liabilities		54.62	72.33
Current Liabilities			
a) Financial Liabilities			
i) Borrowings		67.54	42.05
ii) Trade Payables		34.28	67.54
b) Other Current Liabilities		64.87	90.11
c) Current Provisions		11.93	11.88
Total Current Liabilities		178.62	211.58
TOTAL EQUITY AND LIABILITIES		917.49	959.00



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006


NOTES TO THE FINANCIAL RESULTS :-

- 1) The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on 30 th May,2019.
- 2) The above results of the Company has been audited by the Statutory Auditors and they have issued an unqualified audit opinoin on the same.
- 3) The Company is primarily engaged in the business of manufacturing Pharmaceutical Formulations and there is no other reportable segment.
- 4) Previous figures have been regrouped/ rearranged / reclassified, wherever necessary.

MUMBAI.

For and on behalf of the Board
COLINZ LABORATORIES LTD.
CIN NO : L24200MH1986PLC041128

Dr MANI L. S.
(Director & Company Secretary)
(DIN NO : 00825886)



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006



VORA & ASSOCIATES
CHARTERED ACCOUNTANTS

101-103, REWA CHAMBERS
31, NEW MARINE LINES
MUMBAI - 400 020. INDIA

☎ 022-2200 5933 - 2200 5934
022-2206 3289 - 6615 5599
🌐 www.cavoras.com
✉ office@cavoras.com
cavoras@gmail.com

Ref: MAV/19/CLL/1305

INDEPENDENT AUDITOR'S REPORT

To,
Board of Directors,
COLINZ LABORATORIES LIMITED

We have audited the accompanying statements of financial results of **COLINZ LABORATORIES LIMITED** for the year ended 31st March 2019, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR / CFD / FAC / 62 / 2016 dated July 5, 2016.

This Statement is the responsibility of the Company's Management and is approved by the Board of Directors. The Statement as it relates to the quarter ended March 31, 2019, has been compiled from the related interim financial statements prepared in accordance with Ind AS 34 "Interim Financial Reporting" as it relates to the year ended March 31, 2019, has been compiled from the related annual financial statements prepared u/s 133 of the Companies Act, 2013 read with relevant rules thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such interim financial statements and annual financial statements.

We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirement and plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including assessment of the risks of the material misstatements of the financial statement, whether due to fraud or error. In making those risks assessments, the auditor considers internal financial controls relevant to the Company's preparation and fair presentation of the statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal financial controls. An audit also includes evaluating the appropriateness of the accounting policies used and reasonableness of the accounting estimates made by the Management as well as evaluating the overall presentation of the statement.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a reasonable basis for our audit opinion.





VORA & ASSOCIATES
CHARTERED ACCOUNTANTS

101-103, REWA CHAMBERS
31, NEW MARINE LINES
MUMBAI - 400 020. INDIA

☎ 022-2200 5933 - 2200 5934
☎ 022-2206 3289 - 6615 5599
🌐 www.cavoras.com
✉ office@cavoras.com
cavoras@gmail.com


In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR / CFD / FAC / 62 / 2016 dated July 5, 2016 in this regard; and
- (ii) give a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net Profit, Total comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2019.

For VORA & ASSOCIATES
CHARTERED ACCOUNTANTS
(ICAI Firm Reg. No.: 111612W)

MAYUR A. VORA
PARTNER

(Membership No.: 030097)



PLACE: MUMBAI

DATED: 30 MAY 2019

Date : 30-05-2019

To,
The General Manager
Dept. of Corporate Services
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai — 400 001

SCRIPCODE: 531210

Sub.: Declaration pursuant to Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in respect of Audit Report with unmodified opinion.

Dear Sir/Madam,

With reference to the captioned subject, please note that the Board of Directors in their meeting held Today, Thursday, May 30, 2019 approved Audited Financial Statements for the quarter and year ended March 31, 2019.

Further as required in terms of Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and circular issued in this regard, we hereby declare and confirm that the Statutory Auditors of the Company M/s. Vora & Associates, Chartered Accountants Mumbai (Firm Registration No - 0111612W) have issued the Audit Report with unmodified opinion in respect of Audited Results for the quarter and year ended 31st March, 2019.

Kindly take the same on your record.

Thanking You,

Yours Faithfully,

For Colinz Laboratories Ltd.


Dr. Mani L. S.
Director-Legal, Corporate Affairs & Company Secretary



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006